Novavax (NASDAQ:NVAX) announced Friday that it has reached an agreement with retailers and prominent Group Purchasing Organizations (GPOs) to distribute its protein-based COVID-19 vaccine in the U.S. The company mentioned that it received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on October 3, 2023.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
According to the announcement, the COVID-19 vaccine is the first protein-based vaccine in the United States. Novavax said the vaccine will help prevent the spread of the virus in individuals aged 12 and older this vaccination season.
For widespread use, the company said families can buy the vaccine at retailers such as Costco, CVS Pharmacy, Giant, Publix, Rite Aid, and Stop & Shop. Furthermore, Novavax said the vaccine will also be available through various government entities and added that its agreement with GPOs will ensure the drug gets to every corner of the country.
What is the Prediction for Novavax Stock?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on NVAX stock based on two Buys, zero Holds, and one Sell assigned in the past three months, as indicated by the graphic above. Furthermore, the average NVAX price target of $18.33 per share implies 167.98% upside potential.
